Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 BIIB059 study in adults with active systemic lupus erythematosus
MOH_2022-01-18_010561Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of litifilimab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Biogen. Started Jan 2022; status: active, not recruiting.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2022-01-18_010561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-18_010561.